Bendamustine plus rituximab noninferior to standard therapy in NHL, mantle ... Healio In patients with slowly progressing non-Hodgkin's lymphoma or mantle cell lymphoma, a regimen of bendamustine and rituximab is noninferior to standard treatment in terms of response rate and safety profile, according to findings from the BRIGHT study. |
